BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23810128)

  • 1. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.
    Morgan WJ; Wagener JS; Yegin A; Pasta DJ; Millar SJ; Konstan MW; ;
    J Pediatr; 2013 Oct; 163(4):1152-7.e2. PubMed ID: 23810128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of Antibiotic Treatment to Recovery after Acute FEV
    Morgan WJ; Wagener JS; Pasta DJ; Millar SJ; VanDevanter DR; Konstan MW;
    Ann Am Thorac Soc; 2017 Jun; 14(6):937-942. PubMed ID: 28324670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased rate of lung function decline in Australian adolescents with cystic fibrosis.
    Welsh L; Robertson CF; Ranganathan SC
    Pediatr Pulmonol; 2014 Sep; 49(9):873-7. PubMed ID: 24178906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.
    Ren CL; Konstan MW; Yegin A; Rasouliyan L; Trzaskoma B; Morgan WJ; Regelmann W;
    J Cyst Fibros; 2012 Jul; 11(4):293-9. PubMed ID: 22445849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
    Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J
    BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.
    Konstan MW; Wagener JS; Pasta DJ; Millar SJ; Jacobs JR; Yegin A; Morgan WJ;
    Pediatr Pulmonol; 2011 Jun; 46(6):545-53. PubMed ID: 21438174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.
    Kerem E; Corey M; Gold R; Levison H
    J Pediatr; 1990 May; 116(5):714-9. PubMed ID: 2109790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung Clearance Index to Track Acute Respiratory Events in School-Age Children with Cystic Fibrosis.
    Perrem L; Stanojevic S; Shaw M; Jensen R; McDonald N; Isaac SM; Davis M; Clem C; Guido J; Jara S; France L; Solomon M; Grasemann H; Waters V; Sweezey N; Sanders DB; Davis SD; Ratjen F
    Am J Respir Crit Care Med; 2021 Apr; 203(8):977-986. PubMed ID: 33030967
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
    Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
    Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid lung function decline in adults with early-stage cystic fibrosis lung disease.
    Dasenbrook EC; Fink AK; Schechter MS; Sanders DB; Millar SJ; Pasta DJ; Mayer-Hamblett N
    J Cyst Fibros; 2020 Jul; 19(4):527-533. PubMed ID: 31870629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.
    Wolter DJ; Onchiri FM; Emerson J; Precit MR; Lee M; McNamara S; Nay L; Blackledge M; Uluer A; Orenstein DM; Mann M; Hoover W; Gibson RL; Burns JL; Hoffman LR;
    Lancet Respir Med; 2019 Dec; 7(12):1027-1038. PubMed ID: 31727592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis.
    Schneiderman JE; Wilkes DL; Atenafu EG; Nguyen T; Wells GD; Alarie N; Tullis E; Lands LC; Coates AL; Corey M; Ratjen F
    Eur Respir J; 2014 Mar; 43(3):817-23. PubMed ID: 24176992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis.
    VanDyke RD; McPhail GL; Huang B; Fenchel MC; Amin RS; Carle AC; Chini BA; Seid M
    Ann Am Thorac Soc; 2013 Jun; 10(3):205-12. PubMed ID: 23802816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic duration and changes in FEV
    Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
    BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung function decline from adolescence to young adulthood in cystic fibrosis.
    Vandenbranden SL; McMullen A; Schechter MS; Pasta DJ; Michaelis RL; Konstan MW; Wagener JS; Morgan WJ; McColley SA;
    Pediatr Pulmonol; 2012 Feb; 47(2):135-43. PubMed ID: 22241571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in lung function is associated with worse clinical outcomes in cystic fibrosis.
    Heinzmann-Filho JP; Pinto LA; Marostica PJ; Donadio MV
    J Bras Pneumol; 2015; 41(6):509-15. PubMed ID: 26785959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do cystic fibrosis centres with the lowest FEV
    Hoo ZH; Campbell MJ; Curley R; Walters SJ; Wildman MJ
    J Cyst Fibros; 2018 May; 17(3):360-367. PubMed ID: 29074367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.